Cancer biomarkers are measurable indicators of biological processes associated with tumor development, progression, or response to therapy. They include genetic mutations, proteins, metabolites, imaging features, and epigenetic changes that can be detected in tissues, blood, urine, or other body fluids. Biomarkers play critical roles in early detection, diagnosis, prognosis, monitoring of treatment response, and selection of targeted therapies.

Examples include HER2 in breast cancer, EGFR mutations in lung cancer, and PSA in prostate cancer. Advances in high-throughput technologies and liquid biopsy platforms have enabled non-invasive, real-time biomarker discovery and analysis, revolutionizing cancer diagnostics and treatment personalization. Despite their promise, clinical translation of biomarkers requires rigorous validation, standardization, and regulatory approval. Challenges such as tumor heterogeneity, dynamic biomarker expression, and data interpretation remain areas of active investigation.

Journal of Cancer Biology and Treatment encourages original research and reviews on novel biomarker identification, validation studies, and clinical utility in cancer management. We especially welcome studies that integrate biomarkers with precision medicine, treatment stratification, and patient monitoring to support more informed and adaptive cancer care strategies.